SAB Biotherapeutics Inc (SABS) — Financial Flexibility Index
SAB Biotherapeutics Inc (SABS) has a Financial Flexibility Index of -0.74x as of December 2025. Free cash flow of $-15.84 Million (operating CF $-16.78 Million minus capex $933.15K) represents -1% of total liabilities ($21.32 Million). Also explore net asset growth rate of SAB Biotherapeutics Inc to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SAB Biotherapeutics Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for SAB Biotherapeutics Inc across 7 annual periods. Check SAB Biotherapeutics Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for SAB Biotherapeutics Inc (2019–2025)
Year-by-year free cash flow to debt coverage for SAB Biotherapeutics Inc. For the full company profile including market capitalisation, see SAB Biotherapeutics Inc market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.06x | $-43.84 Million | $-44.78 Million | $21.32 Million | ▼ -10.4% |
| 2024 | -1.86x | $-33.95 Million | $-34.29 Million | $18.23 Million | ▼ -99.2% |
| 2023 | -0.94x | $-24.92 Million | $-25.12 Million | $26.64 Million | ▲ +12.8% |
| 2022 | -1.07x | $-21.29 Million | $-23.46 Million | $19.85 Million | ▼ -453.4% |
| 2021 | 0.30x | $12.93 Million | $1.99 Million | $42.59 Million | ▼ -76.6% |
| 2020 | 1.30x | $22.74 Million | $10.00 Million | $17.53 Million | ▲ +406.1% |
| 2019 | -0.42x | $-8.61 Million | $-9.21 Million | $20.31 Million | — |